Full-Time

Commercial Data Analyst

X, F","M","On site

Posted on 12/13/2025

Sartorius

Sartorius

1,001-5,000 employees

Bioprocess and laboratory solutions provider

No salary listed

Germany

In Person

Category
Data & Analytics (1)
Required Skills
Python
Apache Spark
Machine Learning
SAP Products
Tableau
Salesforce
Databricks
Snowflake
Requirements
  • Master’s degree in Economics, Statistics, Finance, Data Analytics, Engineering, Computer Science or similar qualification
  • Several years of experience in data analytics and reporting and strong project management skills with the ability to manage multiple projects simultaneously
  • Proven track record of driving impactful analytics projects and enabling business stakeholders with actionable insights
  • Exceptional quantitative and qualitative analytical skills, with the ability to analyze data, identify trends, diagnose root causes, and draw actionable conclusions
  • Proficient in building dashboards with visualization tools, particularly Tableau
  • Experience with Customer Segmentation and Stratification is highly valued
  • Expertise in Python/PySpark for data manipulation and modeling
  • Proficient in Snowflake and Tableau, with a strong emphasis on these tools as assets
  • Experience with Generative AI and Machine Learning for enhancing business outcomes is a plus
  • Familiarity with Salesforce.com and other enterprise solutions like SAP ERP is highly desirable
  • A self-driven, can-do attitude with a continuous improvement mindset
  • Fluent in English and additional European languages are an advantage
Responsibilities
  • Lead end‑to‑end project lifecycles, from understanding business challenges to designing, deploying, and operationalizing analytics solutions
  • Collaborate closely with sales, marketing, and customer‑facing teams to design intuitive, user‑centric tools that empower stronger customer interactions and clearer commercial next steps
  • Develop advanced sales tools and digital products that enhance productivity, streamline daily workflows, and guide strategic and tactical decision‑making
  • Design and build dashboards and analytics applications that illuminate customer insights, opportunity potentials, whitespace, and performance trends
  • Partner with data engineers, analysts, and data scientists to design scalable data models and integrated analytics capabilities
  • Engineer robust data pipelines by integrating diverse data sources into cloud platforms such as Databricks and Snowflake
  • Enhance sales readiness and effectiveness by shaping tools that improve account planning, opportunity management, customer follow‑up discipline, and pipeline visibility
  • Strengthen commercial decision‑making by translating complex data into actionable insights that guide customer strategy and commercial execution
  • Drive continuous improvement by evaluating tool usage, gathering feedback, and iterating features to maximize adoption and impact
  • Mentor and support fellow Data & Analytics professionals, fostering best practices and elevating analytics maturity across the organization
  • Contribute to data governance and long‑term analytics strategy, ensuring data quality, trust, and sustainable growth of the analytics ecosystem
Desired Qualifications
  • Experience with Generative AI and Machine Learning for enhancing business outcomes is a plus
  • Familiarity with Salesforce.com and other enterprise solutions like SAP ERP is highly desirable
  • Fluent in English and additional European languages are an advantage

Sartorius provides laboratory and bioprocessing equipment and services for the biopharmaceutical industry. Its two divisions, Bioprocess Solutions and Lab Products & Services, supply systems, consumables, and analytics used in biotech drug and vaccine development and production. It differentiates itself with a long history, an integrated portfolio, global support, and acquisitions like BioOutsource to offer end-to-end solutions. Its goal is to help biopharmaceutical companies develop and manufacture biotech products more reliably and at scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Simplify Jobs

Simplify's Take

What believers are saying

  • Q4 2025 revenue grew 7.6% to over €3.5 billion.
  • The Eveo platform targets CAR-T costs down 90% and output quadrupled.
  • MatTek adds $20 million-plus sales and 3D microtissue models for preclinical workflows.

What critics are saying

  • Lab Products and Services grew just 0.2% in Q4 2025.
  • The €650 million bond matures in autumn 2026 after the new €500 million placement.
  • Eveo's 2027 deliveries leave validation risk unresolved until customer orders begin.

What makes Sartorius unique

  • Founded in 1870, Sartorius built precision balances before bioprocessing.
  • Bioprocess Solutions leads with filtration, fermentation, cell culture, and fluid management.
  • The 2007 Stedim merger created a global single-use bioprocessing platform.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Sartorius who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Flexible Work Hours

Wellness Program

Professional Development Budget

Company News

Sartorius AG
May 6th, 2026
Sartorius completes placement of bond with a volume of 500 million euros

May 6, 2026 – Sartorius has successfully issued a bond with a volume of 500 million euros via its Dutch subsidiary Sartorius Finance B.V.. The issue was targeted at institutional investors and met with strong demand, being more than 4 times oversubscribed.

The Associated Press
Mar 16th, 2026
Sartorius launches platform to cut CAR-T manufacturing costs by 90% and quadruple output

Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.

Yahoo Finance
Feb 3rd, 2026
Sartorius grows revenue 7.6% to €3.5B with EBITDA margin expanding to 29.7%

Sartorius AG reported strong Q4 2025 results, with revenue growing 7.6% in constant currencies to over €3.5 billion, exceeding full-year guidance. The company's EBITDA margin expanded 170 basis points to 29.7%, whilst underlying net profit increased 18%. The bioprocess solutions division drove growth with 9.5% revenue increase in constant currency, supported by strong double-digit growth in recurring revenue. However, the lab products and services division remained essentially flat at 0.2% growth, facing challenges from unfavorable product mix. Sartorius improved its net debt to EBITDA ratio from 3.96 times to 3.55 times, demonstrating financial discipline. The company set a broad guidance range for 2026, citing macroeconomic volatility. Management noted that US onshoring initiatives are expected to impact revenue from 2027 onwards rather than 2026.

Yahoo Finance
Feb 3rd, 2026
Sartorius Stedim Biotech posts 18% profit growth despite equipment softness, cuts debt ratio to 3.55

Sartorius Stedim Biotech reported strong profit growth for Q4 2025, with revenue increasing 7.6% in constant currencies to over €3.5 billion. The EBITDA margin improved 170 basis points to 29.7%, whilst underlying net profit surged 18%. The bioprocess solutions division led growth at 9.5% in constant currency, driven by double-digit growth in recurring revenue that offset continued equipment softness. Order intake grew faster than sales, with the book-to-bill ratio remaining above one. Free cash flow reached €390 million, though operating cash flow declined to €837 million from €976 million previously. The net debt-to-EBITDA ratio improved from 3.96 to 3.55 times. However, the company faces headwinds from a weaker US dollar and set broad 2026 guidance due to market volatility.

Firmenpresse
Sep 16th, 2025
Repairon secures funding for heart therapy

Repairon GmbH, a German biotech company, has secured a substantial Series A funding for its innovative "heart patch" therapy aimed at treating advanced heart failure. The funding, led by Bioventure Management GmbH and co-invested by Satorius AG, will support the Phase 3 trial and GMP production scaling. The heart patch, made from engineered heart muscle, is applied to damaged heart tissue to restore function. Positive preclinical and Phase 1/2 results were published in Nature.

INACTIVE